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ABSTRACT
Given the ethical controversies concerning HIV vaccine trials
(HVTs), we aimed to understand through an exploratory study how
members of institutional review boards (IRBs) in the United States
(US) and research ethics committees (RECs) in South Africa (SA)
view issues concerning the process and content of reviews of
these studies. We mailed packets of 20 questionnaires to 12 US
IRB chairs and administrators and seven REC chairs to distribute
to their members. We received 113 questionnaires (76 from the US
and 37 from SA). In both countries, members tended to be white
males with advanced academic degrees. Compared to the US, SA
members called for ‘major changes’ in HVT protocols more fre-
quently (p = 0.004), and were less likely to think that HVT partici-
pants understood risks and benefits (p = 0.033) or informed
consent forms (p = 0.000). In both countries, members were
divided on several critical issues (e.g. the minimum standard for
treatment for HVT participants who became infected during the
HVT), but agreed that they needed more training. Of the SA
respondents, 40% reported that they were ‘self-taught’ in ethics.
This study, the first we know of to offer quantitative data comparing
US vs. non-US IRBs/RECs, thus suggests key similarities and
differences (e.g. compared to SA respondents, US respondents
appeared to overestimate participants’ understanding of informed
consent), along with needs for education. These initial exploratory
data in this area have important implications for IRBs, RECs,
policy-makers and scholars concerning future practice, training,
policy, and investigations in research ethics, and prevention and
treatment of HIV and other diseases in the developing world and
elsewhere.
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The development of safe and effective preventive
HIV vaccines has been seen as critical for stemming
the growing global HIV pandemic,1 yet HIV vaccine
trials (HVTs) have posed difficult ethical dilemmas.2
Little empirical research has been done on how key
stakeholders – for example, policy-makers, clini-
cians, members of institutional review boards
(IRBs) or research ethics committees (RECs) – view
and approach these issues. Yet, such data could be
vital in these areas, helping to move HVTs forward.
Debates about HVTs succeed a long series of ethical
challenges and controversies about HIV since the
onset of the epidemic.3 Though HIV medications are
becoming more available in the developing world,
they help only those already infected; access to
medications, though widening, remains limited (e.g.
increasing from about 1% to 17% of patients in need
in sub-Saharan Africa between 2002 and 2005).4
Historically, vaccines, in general, have also raised
complex ethical quandaries, causing intense debates
in the United States (US) and abroad.5
On several key ethical issues concerning HVTs,
the Joint United Nations Programme on HIV/AIDS
(UNAIDS) failed to reach consensus, and ulti-
mately referred these disagreements to local IRBs/
RECs, which thus now serve as ‘final arbiters’ in
determining whether and how HVTs are conducted
in particular communities.6 Yet, how local IRBs/
RECs view and face these dilemmas generated by
HVTs remains unknown. Some critics consider
UNAIDS’ guidance document too ‘aspirational’
and not sufficiently ‘pragmatic’.7 Local IRBs/RECs
now face several major unresolved controversies
concerning HVTs. For example, ethicists have
intensely debated the minimum standard of treat-
ment for HVT participants who become HIV-
infected while participating in the trial, with some
critics arguing that the standard should be the
highest available in the sponsoring country rather
than the highest available or standard level of treat-
ment in the host country,8 while others argue that
such a standard may not be ‘attainable and sustain-
able’.9 Yet reports about IRB decision-making con-
cerning HVTs have largely been theoretical.10 Thus,
crucial questions remain as to how IRBs/RECs view
and approach these and related issues concerning
HVTs, and differ in doing so. These questions are
important because IRBs/RECs may potentially
benefit from assistance or guidance in clarifying
and/or weighing these issues. Yet, how these dilem-
mas are perceived or handled within IRBs/RECs
remains unknown.
IRBs in the US, and RECs, as they are called in
many other countries, are increasing in number and
importance, reviewing HVTs and other interna-
tional research. But, overall, little empirical research
has been done on IRB/REC members’ views of
ethical issues. A study of 37 REC chairs or admin-
istrators from several African countries indicated
1 B. Bloom. The Highest Attainable Standard: Ethical Issues in AIDS
Vaccines. Science 1998; 279: 186–188; Republic of South Africa:
Department of Health. 2002. Summary Report: National HIV and
Syphilis Antenatal Sero-prevalence Survey in South Africa 2002. Preto-
ria: Department of Health. Available at: www.doh.gov.za/docs/reports/
2002/hiv-syphilis.pdf [Accessed 26 Dec 2006].
2 M. Angell. Ethical Imperialism? Ethics in International Collaborative
Clinical Research. N Engl J Med 1988; 319: 1081–1083; P. Lurie & S.
Wolfe. Unethical Trials of Interventions to Reduce Perinatal Transmis-
sion of the Human Immunodeficiency Virus in Developing Countries. N
Engl J Med 1997; 337: 853–856.
3 R. Bayer. 1991. Private Acts, Social Consequences: AIDS and the
Politics of Public Health. New Brunswick, NJ: Rutgers University Press;
R. Klitzman & R. Bayer. 2003. Mortal Secrets: Truth and Lies in the Age
of AIDS. Baltimore, MD: Johns Hopkins University Press.
4 United Nations Programme on HIV/AIDS (UNAIDS). 2003. Accel-
erating Action Against AIDS in Africa. Geneva: UNAIDS. Available at:
data.unaids.org/UNA-docs/ICASA_Report_2003_en.pdf [Accessed 6
Dec 2006]; United Nations Programme on HIV/AIDS (UNAIDS).
2006. Global Access to HIV Therapy Tripled in Past Two Years, but
Significant Challenges Remain. Geneva: UNAIDS. Press release, 28
March. Available at: http://www.data.unaids.org/pub/PressRelease/
2006/20060328-PR-3by5_en.pdf?preview=true [Accessed 6 Dec 2006].
5 United Nations Programme on HIV/AIDS, 2003, ibid; United
Nations Programme on HIV/AIDS, 2006, ibid.
6 R. Bayer. Ethical Challenges of HIV Vaccine Trials in Less Devel-
oped Nations: Conflict and Consensus in the International Arena.
AIDS 2000; 14: 1051–1057.
7 R. Macklin. Four Forward-looking Guidance Points. Developing
World Bioeth 2001; 1: 121–134.
8 M. Angell. The Ethics of Clinical Research in the Third World. N
Engl J Med 1997; 37: 847–849.
9 R.J. Levine. Some Recent Developments in the International Guide-
lines on the Ethics of Research Involving Human Subjects. Ann N Y
Acad Sci 2000; 918: 170–178.
10 B. Haynes. Scientific and Social Issues of Human Immunodeficiency
Virus Vaccine Development. Science 1993; 260: 1279–1286; J. Feinberg
& A. Japour. Scientific and Ethical Considerations in Trial Design for
Investigational Agent for the Treatment of Human Immunodeficiency
Virus Infection. Clin Infect Dis 2003; 36: 201–206; C. Grady. 1995. The
Search for an AIDS Vaccine: Ethical Issues in the Development and
Testing of a Preventative HIV Vaccine. Bloomington, IN: Indiana Uni-
versity Press; Macklin, op. cit. note 7.
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that they thought their capacity to review HVTs was
‘moderate to limited’ and that they had several
training needs concerning the science and ethics of
HVTs.11 Yet we know of no published study com-
paring IRBs in the US versus RECs in the develop-
ing world in any way; and numerous critical
questions remain as to whether members or boards
and committees in any one country or in different
countries vary in their views and approaches toward
ethical issues and, if so, how. These questions are
vital because IRBs/RECs have been facing criticism
and numerous complex issues. Specifically, discrep-
ancies have been found to exist among IRBs, includ-
ing inconsistencies in their deliberations, approvals12
and applications of ethical standards.13 In addition,
ethical relativism has been intensely debated. Some
argue that bioethics should be universalistic and not
vary between cultures,14 that a ‘common morality’
exists,15 and that embracing ‘ethical relativism’ pre-
cludes the ability to criticize another’s ethical posi-
tion.16 But others argue that ‘ethics are local’ not
universal,17 that ‘multiple moral traditions’ exist
even in the US, that ethical principles should be
amended in different cultural contexts, and that
a ‘common morality’ does not exist.18 Tensions
between universal versus local contexts date from
the founding of IRBs, which were established to be
‘local’, making decisions for an institution,19 though
the principles underlying deliberations were to be
universal. Given discrepancies, some critics call for
national rather than local review of protocols,20
though others disagree.21 Ethicists have debated this
question in the literature,22 but we have found no
prior data on how IRB/REC members themselves
view this question. IRB members’ goals to be impar-
tial have also been criticized as potentially being
elusive, given members’ demographics, since most
are white and male and work at research institu-
tions, and thus may be ‘biased’ in favor of
research.23
In the developing world, these difficulties may
be compounded, as specific challenges emerge in
importing, establishing, and incorporating the idea
of IRBs into other cultures. For example, in one of
the only studies of researchers in the developing
world, 29% said most of their research collaborators
in foreign countries did not speak or read English
well.24 Principal investigators (PIs) and IRB/REC
members in eight countries saw the US IRB review
process as ‘unnecessarily burdensome’ in time and
difficulty,25 and perceived little flexibility in how US
regulations were applied, despite cultural differ-
ences. Moreover, in other cultures, illness itself is11 C. Milford, D. Wassenaar & C. Slack. Resources and Needs of
Research Ethics Committees in Africa: Preparations for HIV Vaccine
Trials. IRB 2006; 28(2): 1–9.
12 J. Bell, J. Whiton & S.Connelly. James Bell Associates. 1998. Evalu-
ation of NIH Implementation of Section 491 of the Public Health Service
Act, Mandating a Program of Protection for Research Subjects. Report
prepared under a National Institute of Health contract, N01-OD-2–
2109. Washington, DC: United States Department of Health and
Human Services.
13 J. Goldman & M. Katz. Inconsistency and Institutional Review
Boards. JAMA 1982; 248: 197–202; A. Doob. The Reliability of Ethical
Reviews: Is it Desirable? Can Psychol 1983; 24: 269–270; W. Eaton. The
Reliability of Ethical Reviews: Some Initial Empirical Findings. Can
Psychol 1983; 24: 14–18.
14 Angell, op. cit. note 2; Lurie & Wolfe, op. cit. note 2.
15 T.L. Beauchamp. A Defense of the Common Morality. Kennedy Inst
Ethics J 2003; 13: 259–274.
16 R. Macklin. 1991. Against Relativism, Cultural Diversity and the
Search for Ethical Universals in Medicine. New York, NY: Oxford
University Press.
17 N. Christakis. Ethics are Local: Engaging Cross Cultural Variation
in the Ethics for Clinical Research. Soc Sci Med 1992; 35: 1079–1091.
18 L. Turner. Zones of Consensus and Zones of Conflict: Questioning
the ‘Common Morality’ Presumption in Bioethics. Kennedy Inst Ethics
J 2003; 13: 193–218; M. Barry. Ethical Consideration of Human Inves-
tigation in Developing Countries: The AIDS Dilemma. N Engl J Med
1992; 319: 1083–1086.
19 See United States Department of Health and Human Services
(HHS). 2005. Code of Federal Regulations. Title 45. Part 46. Protection
of Human Research Subjects. Washington, DC: HHS. Available at:
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm
[Accessed 23 Dec 2006].
20 L. Eckenwiler. Moral Reasoning and the Review of Research Involv-
ing Human Subjects. Kennedy Inst Ethics J 2001; 11: 37–69; M. Chris-
tian et al. A Central Institutional Review Board for Multi-institutional
Trials. N Engl J Med 2002; 346: 1405–1408.
21 D. Phillips. Institutional Review Boards Under Stress: Will they
Explode or Change? JAMA 1996; 276: 1623–1626.
22 Ibid; Eckenwiler, op. cit. note 20; Christian et al., op. cit. note 20.
23 Grady, op. cit. note 10.
24 A. Wichman et al. Collaborative Research Involving Human Sub-
jects: A Survey of Researchers Using International Single Project
Assurances. IRB 1997; 19: 1–6.
25 J. Sugarman et al. 2001. International Perspectives on Protecting
Human Research Subjects. In Ethical and Policy Issues in International
Research: Clinical Trials in Developing Countries: Vol. II. National
Bioethics Advisory Commission (NBAC). Bethesda, MA: NBAC:
E1-E30. Available at: http://www.georgetown.edu/research/nrcbl/nbac/
clinical/Vol2.pdf [Accessed 6 Dec 2006].
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often perceived and treated in fundamentally differ-
ent ways.26
Though seriously under-studied, IRBs in the US
and RECs in the developing world are growing
rapidly, with 3,000–5,000 IRBs now in the US,27
ranging from 5–44 members.28 The mean numbers
of members for high and low volume IRBs are 20
and 10, respectively.29
South Africa (SA) serves as an important country
in which to explore these issues as a case in point
because its HIV prevalence is among the highest in
the world and HVTs are being conducted there. SA
has approximately 23 RECs.30 Of these, 12 are reg-
istered and have assurances with the US Office of
Human Research Protections (OHRP).31
Thus, several critical research questions emerge:
How do members of US IRBs and SA RECs view
and approach these vital issues concerning HVTs?
Controversies about HVTs take place in the context
of, and may reflect, broader debates about IRBs
more generally (e.g. concerning participant under-
standing of consent forms, central versus local
review, ethical relativism, PI wariness of IRBs, etc.).
These areas, such as whether study participants
understand informed consent forms, are important
to ensure adequate and appropriate protections of
human subjects as articulated in the Belmont
Report32 and the Declaration of Helsinki.33 Hence,
debates about reviews of HVTs concern not just the
content of HVTs, but the process of the IRB review
involved, and these areas are consequently critical to
probe. Do US IRBs and SA RECs differ in their
views of process or content of HVT reviews and, if
so, how? Given the lack of available data, and the
controversies involved, this study aimed to shed
initial light on whether and how members of US
IRBs and SA RECs may differ with regard to three
broad areas: 1) content of HVT reviews, 2) process
of HVT reviews, and 3) process and functioning of
IRB/REC reviews in general. Specifically, as an
initial exploratory study in this area, this research
probed several key questions: whether IRBs and
RECs differ in content variables (e.g. perceptions of
HVT participants’ understandings of risks and ben-
efits, placebos and informed consent, approaches
toward ethical debates concerning standards of
treatment for HVT participants who become
infected during the HVT, and decisions about oral
consent in HVTs); HVT-related process issues (e.g.
requests for major changes in HVT protocols,
and IRB/REC disagreements about HVTs); and
general process issues (e.g. types and background of
members, communication with IRBs/RECs in other
countries, needs for central versus local review,
amendment of ethical principles in other countries,
IRB education needs, and views of PI understand-
ings of IRBs). Because little data in these areas
are available, the overall goals were to gain insights
that might help further education, research and
guidelines.
26 R. Fox. 1959. Experiment Perilous. Glencoe: The Free Press; R. Fox
& J. Swazey. 1992. Spare Parts: Organ Replacement in American
Society. New York, NY: Oxford University Press; B. Malinowski. 1950.
Argonauts of the Western Pacific: An Account of Native Enterprise and
Adventure in the Archipelagoes of Melanesian New Guinea. New York,
NY: E.P. Dutton; E.E. Evans-Pritchard. 1937. Witchcraft, Oracles, and
Magic Among the Azande of the Anglo-Egyptian Sudan. Oxford: Clar-
endon Press; J. Camaroff & J. Camaroff. Occult Economies and the
Violence of Abstraction: Note from the South African Postcolony.
American Ethnologis 1999; 26: 279–303.
27 Office of Inspector General. 1998. Final Report on Low Volume Insti-
tutional Review Boards. DHHS Publication No. OEI-01–97–00194.
Washington, DC: United States Government Printing Office. Available
at: http://www.oig.hhs.gov/oei/reports/oei-01-97-00194.pdf [Accessed 6
April 2006].
28 A. Anderson. 2002. RIID Human Subjects Protection Program Best
Practices. Human Subjects Research Review Board Meeting. Frederick:
MD. Seminar presentation, 5 September. Available at: http://
www.geocities.com/artnscience/AO_Anderson_CV/index.html
[Accessed 6 Apr 2006]; United States Department of Health and
Human Services, op. cit. note 19.
29 Bell et al., op. cit. note 12.
30 World Health Organization (WHO)/United Nations Programme on
HIV/AIDS (UNAIDS). African AIDS Vaccine Program (AAVP).
2003. African AIDS Vaccine Program: Inventory. Online: AAVP.
Available at: http://www.saavi.org.za/inventory.htm [Accessed 16 Dec
2006].
31 See Office of Human Research Protections (OHRP). International
Assurances and Components South Africa (106). Available at: http://
www.ohrp.cit.nih.gov/search/asurlst.asp?locationid=228&atype=
f&otype=i&DLST=Submit&ctype=i&key1=F&key2=M&choice=
b&name=AFGHANISTAN [Accessed 16 Jan 2007].
32 The National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research. 1979. The Belmont Report:
Ethical Principals and Guidelines for the Protection of Human Subjects of
Research. Washington, DC: Department of Health, Education, and
Welfare, National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research. Available at: http://www.usd.edu/
oorsch/compliance/SOPs/APPENDIXA.pdf [Accessed 23 Dec 2006].
33 World Medical Association (WMA). 1964. Declaration of Helsinki.
As amended by the WMA 52nd General Assembly, Hong Kong, 1989.
Ferney-Voltaire: WMA. Availaible at: http://www.onlineethics.org/
reseth/helsinki.html [Accessed 23 Dec 2006].
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METHODS
By researching the scientific literature and contact-
ing the HVT Network (HVTN), the HIV Prevention
Trials Network (HPTN), the International AIDS
Vaccine Initiative (IAVI) and the National Insti-
tutes of Health (NIH), we compiled a list of 42 US
institutions that have conducted HVTs in the US
and/or overseas.34 We crosschecked this list with the
database of IRBs with OHRP assurances (dated
Nov 2003). We found that some information on
the OHRP database was outdated (e.g. incorrect
contact information) and not all institutions on our
list were on the OHRP database. The database had
accurate contact information for 27 IRB represen-
tatives, who we then contacted. We received 12
agreements to participate and only one IRB chair
declined to participate, due to its policy that it does
not participate in studies. Our initial research in
2004 indicated that three RECs in SA had reviewed
HVTs. Due to this fact, coupled with the high preva-
lence of HIV in SA, we compiled a list of all 12
RECs in SA that have assurances from OHRP,
including those that have undertaken HVTs. We
contacted three South African medical ethicists
involved in HVTs who suggested the names of seven
institutions that they felt were also likely to have
conducted HIV research. We contacted these RECs
and received seven affirmative replies. We developed
a questionnaire based on a review of the literature
and interviews and discussions with members of 12
US IRBs and 10 developing world RECs. As dis-
cussed above, we designed questions to understand
how IRB/REC members viewed relevant process
and content issues concerning reviews of HVTs. We
pilot tested the questionnaire with five respondents,
and then refined the instrument. We sent question-
naires to chairs, first in the US and then in SA.
Based in part on additional conversations with IRB
members in the interim, we then added several ques-
tions to the instrument mailed to SA. (Instruments
are available upon request from the author.)
We sent packets of 20 questionnaires to each
chair. Prior work showed that mean numbers of
members of high and low volume IRBs are 19.7 and
10.5, respectively.35 IRB chairs were able to make
additional copies or to inform us that they would
like additional questionnaires sent to them, if
needed. We mailed these questionnaires twice to
each of the 12 US and 7 SA representatives who had
agreed to participate and distribute these question-
naires to their members. Past attempts to study
IRBs have been limited because lists of IRB/REC
members are not public knowledge, and in other
prior studies, chairs have often refused to provide
these names.36 Moreover, for an IRB to be observed,
all members must provide informed consent, which
has posed obstacles in terms of feasibility. These
obstacles explain in part why so few studies of IRB/
REC members have been published to date.37
In the present study, the questionnaire did not ask
respondents to provide their name or the names of
their institution or IRB/REC, as the questionnaire
addressed controversial and potentially sensitive
areas about decisions and behaviors of respondents
and their IRB/RECs. Hence, potential respondents
might avoid completing or returning the survey
because of concerns that they or their board or insti-
tution might potentially be identified. Anonymity
was thought to be important to encourage partici-
pation of potential subjects. Potential participants
were also busy professionals. Thus, to reduce the
potential burden to them in terms of time and effort,
the questionnaire was made as short as possible
(i.e. to fit on one piece of paper), though that
limited the number of items that could be included.
For analyses, we performed simple descriptive
statistics and chi-squares to compare respondents
34 See HIV Vaccine Trials Network (HVTN). 2004. HIV Vaccine Trials
Network. Online: HVTN. Available at: http://www.hvtn.org [Accessed
24 Jan 2004]; International AIDS Vaccine Initiative (IAVI). 2003. Inter-
national AIDS Vaccine Initiative. Online: IAVI. Available at: http://
www.iavi.org [Accessed 30 Oct 2003]; HIV Prevention Trials Network
(HPTN). 2006. HIV Prevention Trials Network. Online: HPTN. Avail-
able at: http://www.hptn.org/index.htm [Accessed 23 Jan 2007]; Infor-
mation obtained from HIVNet. Available at: http://www.ahrq.gov/
data/hivnet.htm [Accessed 6 Dec 2006]; Bell et al., op. cit. note 12.
35 T.H. Wagner et al. 2001. Technical Appendix for the Cost of Operat-
ing Institutional Review Boards (IRBs). Presented at Human Subjects
Research Subcommittee – Committee on Science, National Science and
Technology Council, Washington, DC: January 10.
36 R. De Vries & C. Forsberg. What do IRBs Look Like? What Kind of
Support do they Receive? Account Res 2002; 9: 199–216; R. De Vries &
D.A. DeBruin. Ethics Review of Social, Behavioral, and Economic
Research: Where Should we go from Here? Ethics Behav 2004; 14:
351–368.
37 De Vries & Forsberg, ibid.
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from the two countries. IRB approval was obtained
from the author’s institution.
RESULTS
We received a total of 113 completed questionnaires
– including 76 from US IRB members and 37 from
SA REC members, suggesting response rates of
approximately 76/240, (31.7%), and 37/140 (26.4%),
respectively. Tables 1 and 2 summarize demograph-
ics and responses of the sample. In brief, in both the
US and SA, gender differences arose among res-
pondents in highest level of education obtained
(p = 0.003); and in the US, males were also more
likely to be white (p = 0.012), and chairs (p = 0.013).
Of the US respondents, 52 had reviewed HVTs in
the US and 30 had reviewed HVTs in the developing
world. Though all of these US IRBs had in fact at
one point reviewed HVTs, not all current members
reported having done so, or knowing that their IRB
had done so. As indicated in the tables, for the
purpose of analyses, for questions concerning HVTs
in general and in the developing world, we included
only those subjects who had in fact themselves
reviewed a protocol from each of these two catego-
ries, respectively.
Concerning HVTs, of US respondents, most
thought participants in the developing world under-
stood that they might be given a placebo and under-
stood risks and benefits of HVTs ‘very’ or
‘somewhat well’ (vs. ‘poorly’ or ‘somewhat poorly’).
Only 10.6% of these respondents had ever approved
oral consent for these studies. The sample was
divided on issues of standard of treatment for HVT
participants who become HIV-infected during the
HVT. Concerning IRB processes in general, two-
thirds thought their IRB would benefit from addi-
tional education. Respondents were divided on
whether protocols should be reviewed centrally
rather than locally and how often ethical principles
should be ‘amended’ by IRBs/RECs in the develop-
ing world. Almost one-half (47.9%) of US respon-
dents thought their IRB communicates with foreign
IRBs ‘rarely’ or ‘never’.
Most SA respondents thought HVT participants
understood the risks and benefits involved ‘some-
what poorly’ and that study participants in their
country understood consent forms ‘somewhat
poorly’, and 42.3% felt participants understood that
they might be given a placebo ‘poorly’ or ‘somewhat
poorly’. On the minimum standard of treatment
provided to participants of SA HVTs who become
HIV infected, respondents were divided: 63.0%
believed it should be the best available worldwide,
11.1% the best available in South Africa, and 25.9%
the standard treatment in SA. Only 7.4% had ever
approved oral consent for HVTs; 75.8% believed
that they would benefit from additional education
regarding HVTs.
Concerning IRB processes in general, SA respon-
dents were divided as to whether protocols should
be reviewed at a centralized national level rather
than locally; and 70% felt that the ethical principles
used by US IRBs need to be amended by RECs
‘somewhat’ or ‘very much’.
As shown in Table 3, on questions concerning
ethics training, posed to SA REC but not US IRB
members, 40% of SA respondents described them-
selves as ‘self-taught’, with males more likely than
women to do so (p = 0.006).
Comparisons of US versus SA responses revealed
both similarities and differences. SA respondents
had, on average, a higher level of education
(p = 0.043), with over 70.2% holding PhD or MD
degrees (vs. 38.2% of US respondents). Respondents
in SA reported calling for ‘major changes’ in HVT
protocols (p = 0.004), more than did those in the
US. Compared to US respondents, SA members
thought that HVT participants understood risks
and benefits less (p = 0.033) and that participants in
general understood informed consent forms less well
(p = 0.000). In both countries, respondents agreed
that their IRBs rarely approved oral consent for an
HVT and sometimes disagreed about HVTs. In
both countries, most respondents did not feel that
communication with foreign IRBs was adequate
and members were divided on the minimal accept-
able standard of treatment for HVT participants
who became HIV-infected during the HVT.
Respondents also felt that researchers understood
the role of the IRBs/RECs only somewhat well, that
ethical principles needed to be amended somewhat
in the developing world, and that members needed
more education. Among US and SA respondents
combined, there were no gender differences in views
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Table 2. Other Data Collected from United States Institutional Review Boards and South African Research
Ethics Committee Members
US IRB SA REC US vs. SA
Total (%) Total (%) p Value
PROCESS OF HVT REVIEWS
Has your IRB reviewed HVTs in the US?
Yes 52 69.3% N/A N/A
No 23 30.7% N/A N/A
Has your IRB/REC reviewed HVTs in (the developing world/SA)? 0.000
Yes 30 41.1% 27 77.1%
No 43 58.9% 8 22.9%
Has your IRB/REC called for major changes in HVT protocols?* 0.004
Very often 2 4.1% 6 25.0%
Sometimes 26 53.1% 16 66.7%
Rarely 17 34.7% 2 8.3%
Never 4 8.2% 0 0.0%
Have IRB/REC members disagreed concerning HVT protocols?*
Very often 3 6.0% 3 12.5%
Sometimes 29 58.0% 15 62.5%
Rarely 13 26.0% 6 25.0%
Never 5 10.0% 0 0.0%
Have you ever approved oral consent for an HVT protocol?**
Yes 5 10.6% 2 7.4%
No 42 89.4% 25 92.6%
CONTENT OF HVT REVIEWS
Do you think HVT participants in the developing world/SA understand the risks
& benefits involved in HVTs?**
0.033
Very well 1 3.8% 6 23.1%
Somewhat well 13 50.0% 5 19.2%
Somewhat poorly 11 42.3% 15 57.7%
Poorly 1 3.8% 0 0.0%
Do participants in the developing world/SA understand that they may be given a
placebo?**
Very well 1 3.8% 5 19.2%
Somewhat well 13 50.0% 10 38.5%
Somewhat poorly 10 38.5% 11 42.3%
Poorly 2 7.7% 0 0.0%
Minimum standard of treatment for participants who become HIV-infected during
an HVT in the developing world/SA
Best avail worldwide 15 55.6% 17 63.0%
Best avail in host country 4 14.8% 3 11.1%
Standard in host country 8 29.6% 7 25.9%
How adequately is the privacy of research participants in HVTs protected in the
developing world?**
Very adequately 8 32.0% 13 52.0%
Somewhat adequately 14 56.0% 11 44.0%
Somewhat inadequately 3 12.0% 1 4.0%
Very inadequately 0 0.0% 0 0.0%
Do you think your IRB/REC would benefit from additional education concerning
HIV vaccine trials?
Yes 40 65.6% 25 75.8%
No 21 34.4% 8 24.2%
ISSUES CONCERNING GENERAL IRB PROCESS
Do you think research participants adequately understand informed consent
forms?
0.000
Very well 1 1.4% 3 8.6%
Somewhat well 50 69.4% 9 25.7%
Somewhat poorly 16 22.2% 20 57.1%
Poorly 5 6.9% 3 8.6%
Does your IRB communicate with IRBs/RECs in other countries adequately?
Always 6 13.0% 10 33.3%
Sometimes 18 39.1% 11 36.7%
Rarely 17 37.0% 7 23.3%
Never 5 10.9% 2 6.7%
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of the process or content of HVT reviews or the
process of IRBs. We considered doing multivariate
modeling: however, the numbers of respondents
appeared to be relatively low for this purpose.
CONCLUSIONS
This study is one of the first to offer data on US IRB
decision-making, and the first that we know of to
compare IRBs/RECs in the US and the developing
world. Critical similarities and differences between
IRB/REC members in the two countries emerged.
The existence of these similarities in the composition
and views of members across countries is notewor-
thy and potentially reassuring to those who are con-
cerned about discrepancies between IRBs and the
trustworthiness of IRBs/RECs outside the US.
Critical differences between countries arose con-
cerning perceived misunderstandings by HVT par-
ticipants. Respondents in the US, more than in SA,
thought that research participants understood risks
and benefits involved in HVTs and consent forms in
general. These differences may emerge because SA
respondents have more ‘on the ground’ experience
with conducting research in the developing world
and are thus more aware of problems in comprehen-
sion of key issues, while, from greater distances, US
IRBs’ assume that participants understand IRB-
approved forms. Yet this discrepancy is of concern.
Studies have demonstrated relatively high rates of
participant misunderstanding of informed consent
Table 2. Continued
US IRB SA REC US vs. SA
Total (%) Total (%) p Value
Should protocols be reviewed at a centralized, national level rather than locally?
Always 1 1.4% 3 8.6%
Sometimes 30 43.5% 13 37.1%
Rarely 28 40.6% 12 34.3%
Never 10 14.5% 7 20.0%
Do the ethical principles used by IRBs in the US need to be amended by
IRBs/RECs in the developing world/SA?
Very much 4 7.7% 7 23.3%
Somewhat 24 46.2% 14 46.7%
Rarely 15 28.8% 6 20.0%
Never 9 17.3% 3 10.0%
Do researchers understand and appreciate the role of the IRB/REC?
Very much 12 16.2% 5 13.9%
Somewhat well 60 81.1% 28 77.8%
Somewhat poorly 2 2.7% 3 8.3%
Poorly 0 0.0% 0 0.0%
* Indicates answers recorded only for those subjects who had reviewed HVTs in US or SA.
** Indicates answers recorded only for subjects who had reviewed HVTs for a developing country/SA.
Table 3. Questions Collected from South African Research Ethics Committees but not United States’
Institutional Review Boards
Total Male Female p Value
How would you describe your level of expertise in the field of ethics?
Basic 11 30.6% 8 40.0% 2 13.3%
Intermediate 16 44.4% 7 35.0% 9 60.0%
Advanced 9 25.0% 5 25.0% 4 26.7%
What does your ethics training comprise of? 0.006
Self-taught 13 40.0% 12 63.1% 1 6.7%
Attendance of short courses/seminars 15 42.9% 6 31.6% 9 60.0%
Diploma level 1 2.9% 0 0.0% 1 6.7%
Postgraduate level 5 14.3% 1 5.3% 4 26.7%
Views of HVT Review among IRBs and RECs 215
© 2007 The Author. Journal compilation © 2007 Blackwell Publishing Ltd.
in the West38 and in the developing world.39 The
present data further highlight another aspect of this
misunderstanding: that US IRB members assume
participants comprehend studies when that may not
be the case. US IRB beliefs in the effectiveness of the
informed consent process pose potential problems,
as these beliefs may undermine effective efforts to
obtain truly informed consent, which is ethically
necessary. Potentially, in the debate about central-
ized versus localized IRBs, findings such as these
could more fully support the existence of local IRBs
that presumably would best be able to assess such
details concerning participant comprehension.
These findings also pose broader questions about
the optimal ability of US IRBs to make decisions
that might be made more knowledgeably locally, in
the developing world. Other reports have suggested
that US IRBS are seen as being overly concerned
with consent forms, rather than participant compre-
hension per se.40 The present data highlight another
aspect of this phenomenon that may partly underlie
it: IRB members’ belief that participants in fact
understand these forms. These data also highlight
the need for IRBs in the developing world and the
US to communicate better, given differences in
views of this communication and in perceptions of
HVT participant comprehension.
The fact that, in both countries, most members
thought they needed additional training, despite edu-
cational efforts over the past few years, indicates the
importance of establishing and maintaining appro-
priate educational initiatives. The finding that 40%
of SA members reported being self-taught is also of
concern. Future research can explore whether those
who are ‘self-taught’ view or approach ethical issues
differently than others (i.e. those who have had
more formal ethics training) and, if so, how; of what
self-teaching consists (e.g. the range, quantity, and
content of self-education in ethics); how widespread
it is (i.e. in the US and other countries); how it
may be limited, and can best be complemented or
enhanced (i.e. in what specific areas further training
is required).
In both countries, members were divided on
several issues: for example, on the minimum stan-
dard for treatment for participants who become
HIV-infected during HVTs. While, a priori, one
might have expected SA members to be more likely
to favor the highest possible standard (i.e. wanting
the most for their comparatively resource-poor
country), 37.1% of members in SA and 44.4% of
members in the US thought that other lesser levels
of treatment were appropriate and responses from
the two countries did not significantly differ. Hence,
a sizable proportion of members appeared to be
pragmatic in their approach – choosing not the
highest, but a more feasible standard – rather than
adhering rigidly to universalistic principles that
treatment should not vary at all between countries.
In both countries, respondents were also almost
equally divided on needs for local versus ‘central-
ized national level’ review. Future research can
investigate what factors separate those who think
that central rather than local review is appropriate
and on what protocols members think central
review would be advantageous. Prior discussions
have focused on whether central (vs. local) review is
better rather than on what specific types of proto-
cols (other than multi-site studies in general) would
be best for each approach.41 The fact that respon-
dents themselves are divided also needs to be taken
into consideration by policy-makers considering
whether to alter the current system of local review.
Clearly, policy-makers need to consider not only
whether such a central system would, in the
abstract, ensure more optimal reviews, but how
such a system would be instituted, given that IRB/
REC members are divided about it, with many
opposing it.
In both countries, respondents were also split as
to whether principles need to be ‘amended’ in the
developing world. As mentioned earlier, ethical rela-
tivism has received attention,42 with commentators
38 S. Joffe et al. Quality of Informed Consent in Cancer Clinical Trials:
A Cross-sectional Survey. Lancet 2001; 358: 1772–1777.
39 M. Krosin et al. Problems in Comprehension of Informed Consent in
Rural and Peri-urban Mali, West Africa. Clin Trials J 2006; 3: 306–313.
40 Sugarman et al., op. cit. note 25.
41 J. Gold & C.S. Dewa. Institutional Review Boards and Multisite
Studies in Health Services Research: Is there a Better Way? Health Serv
Res 2005; 40: 291–307; R.D. Pentz & A.F. Khayat. The Poster Child for
the Need for Central Review of Research Protocols: The Children’s
Oncology Group. Camb Q Healthc Ethics 2004; 13: 359–365.
42 Angell, op. cit. note 2; Lurie & Wolfe, op. cit. note 2; Beauchamp, op.
cit. note 15; Macklin, op. cit. note 16; Christakis, op. cit. note 17;
Turner, op. cit. note 18; Barry, op. cit. note 18.
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on each side. Yet the present data suggest that reso-
lution of this issue may be much more complicated
than some observers may anticipate and that more
than simple binary approaches toward relativism
(i.e. of pro and con) may be needed. Rather, chal-
lenges emerge of developing appropriately nuanced
understandings of underlying issues and assump-
tions, exploring factors involved and integrating
these considerations and complexities into profes-
sional training. Future research can investigate
when, how and why some members think principles
need to be amended.
Of note, in both countries, the majority of
members were white. In SA, the low numbers of
blacks on committees was particularly striking.
Future research can explore the fact that gender was
associated with professional training and, in the US,
with IRB role. Gender, though not significantly
associated here with differences in views of the
content or process of reviews, may be related to
other aspects of these areas that were not probed
here (e.g. in studies that explicitly involve gender
roles, such as research concerning reproductive
issues).
The problem of achieving ethnic diversity in
membership of IRBs/RECs appears not to be
unique to one country and may reflect and contrib-
ute to tensions more generally between medical
researchers and lay communities. Of note, subse-
quent in-depth semi-structured interviews that I
have been conducting in SA with REC members,
following the administration of this questionnaire
(and on which I plan to report separately), have
indicated that these members view this unequal
ethnic distribution as a problem and are trying to
resolve it but face several critical obstacles. Commu-
nity members may lack the education to understand
fully complicated scientific protocols under review.
Community members who have achieved sufficient
education, and are thus health care professionals
themselves, may no longer at that point truly be
‘community members’ but rather members of the
research enterprise, broadly defined. RECs require
long hours and dedication, and community
members often face impediments of competing time
pressures. Hence, REC members report that com-
munity members often ‘drop out’ of RECs after
only a few months or a year. These problems could
potentially be addressed not just by individual insti-
tutions, but at larger levels as well (e.g. through
WHO or UNESCO). Specifically, needs exist to
develop programs and incentives to engage and
educate community members broadly about
research and RECs.
This study has several potential limitations. The
sample size is comparatively small, but still large
enough to illustrate and highlight key issues that
require further attention by members of the research
enterprise (e.g. IRB/REC members and policy-
makers) and by researchers in ethics, and others.
Though the response rates are not as high as some
studies of other populations, IRB/REC members
are a particularly difficult group to study because, as
described above, their institutions do not ordinarily
reveal their names. As mentioned, these logistical
obstacles to studying IRB/REC members have led
to relatively few studies being conducted to date.
The response rates here are also reasonable for
studies of busy health care professionals.43 In com-
parison, some other mail surveys track whether indi-
vidual survey recipients have responded yet and, if
not, re-contact them and mail surveys three times.
The fact that IRBs will not reveal membership to
researchers, and the need to maintain anonymity of
respondents, hampered possibilities of re-contacting
recipients individually. A structured questionnaire
was used, which did not allow participants to elabo-
rate responses to questions and terms (e.g. how
exactly ethical principles might ‘need to be amended
in the developing world/SA’). However, these
domains can be investigated further in future
research. Despite these limitations, these data are
very valuable, offering initial exploratory data in
this area. Though SA is not representative of all
developing countries, as a sub-Saharan African
nation in the post-apartheid era, it shares many
challenges in terms of epidemics of HIV and other
43 R. Klitzman, A. Bodkin & H.G. Pope. Sexual Orientation and Asso-
ciated Characteristics Among North American Academic Psychiatrists.
J Sex Res 1998; 35: 282–287; A. Bodkin, R. Klitzman & H. Pope.
Treatment Orientation and Associated Characteristics Among North
American Academic Psychiatrists. J Nerv Ment Dis 1995; 184: 729–735;
R.R. Acton et al. Knowledge, Attitudes, and Behaviors of Alabama’s
Primary Care Physicians Regarding Cancer Genetics. Acad Med 2000;
75: 850–852; E. Mountcastle-Shah & N.A. Holtzman. Primary Care
Physicians’ Perceptions of Barriers to Genetic Testing and their Will-
ingness to Participate in Research. Am J Med Genet 2000; 94: 409–416.
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infectious diseases, low levels of education and lit-
eracy, post-colonial political problems, and limited
resources. Further research can examine these issues
in other countries as well. As noted, for this pilot
study we did not gather data on names of institu-
tions or IRB/RECs (given that some institutions
have more than one IRB) in order to ensure
maximal protection of confidentiality. However, all
of the chairs to whom questionnaires had been sent
had first agreed to distribute these surveys to their
members. Hence, it is reasonable to assume that at
least some members from each committee com-
pleted and returned the questionnaire. Future
research can explore differences between views of
members of any particular IRB/REC, and compare
individual IRB/RECs. Due to the intent to keep the
questionnaire as short as possible, to reduce the
burden on busy professionals, we were not able to
probe certain areas in further depth. Hence, we left
certain terms (e.g. about how often IRBs request
‘major changes’, and ‘disagree’, etc.) to be defined
by participants themselves. Though some questions
may be vague, the data suggest similarities and dif-
ferences in IRB/REC members’ views and practices
concerning these domains that future research can
investigate further. Thus, though these potential
limitations may possibly lower the generalizability
of the study, this research nevertheless provides
important suggestive data. These exploratory data
can provide vital background for future larger
studies that can pursue these areas further among
larger numbers of committees, using surveys that
request names of IRBs and institutions as well.
Another potential limitation is the possible effect
of multiple comparisons. The significance levels
presented are not corrected for the effects of mul-
tiple comparisons. Chance associations may have
occurred due to the number of comparisons, par-
ticularly when we assessed comparisons of marginal
statistical significance. However, classical Bonfer-
roni corrections tend to be overly conservative in
research such as this. In addition, a consistent
overall pattern emerged broadly across variables
and these findings appear to have a certain face
validity. We present the findings here without cor-
rection, allowing readers to judge the results for
themselves. As mentioned, the findings can be
pursued more thoroughly in future studies as well.
As suggested above, given how comparatively
few studies have been conducted on IRBs, despite
these limitations, these descriptive findings are thus
important. Surveys were here distributed to chairs,
and because these questionnaires focused on one
issue – HVTs, which have raised wide public dis-
cussion – IRB/REC chairs and members appeared
to recognize the value of the project and conse-
quently may have been amenable to participating.
Future researchers may want to use similar
approaches – making studies of IRBs ‘issue spe-
cific’. However, these data also reveal another
obstacle to research of which future studies will
need to take account: that IRBs/RECs may be hard
to study about a particular issue, in part because
members regularly ‘rotate off’.
In sum, these data shed important initial light on
several crucial areas concerning the process and
content of IRB/REC reviews of HVTs in the devel-
oping and the developed world. Given rapidly
increasing globalization and collaboration between
developed and developing nations in investigating a
variety of disorders, this study thus has key impli-
cations for future research and scholarship (in both
ethics and prevention of HIV and other disorders),
policy, and practice concerning the ethical review of
a widening range of study protocols in upcoming
years.
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